BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
NCT07413705
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or postmenopausal without an alternative medical cause before enrollment in the study and are aged 40 years and older. The main question it aims to answer is: Does the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices improve depressive symptoms and urinary incontinence?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depressive Symptoms
- Urinary Incontinence
- Sexual Dysfunction
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- BTL Industries Ltd.
- Last updated on ClinicalTrials.gov
- February 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Luxury Psychiatry Clinic · Winter Garden, FL
Massachusetts · 1
- Aesthetic + Mind MD · Wellesley, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.